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OBJECTIVE: Two percent of all children and 4% of all adoles-
cents in the United States have been diagnosed with Major
Depressive Disorder (MDD). Unfortunately, many children and
adolescents who have MDD never receive proper treatment. Of
those who do receive treatment, antidepressants are commonly
utilized. In October, 2004 the US Food and Drug Administration
(FDA) issued a Public Health Advisory to warn that increased
risk of suicidal thoughts and behaviors may be associated with
the use of antidepressant medications, including SSRIs, in chil-
dren and adolescents. Since this warning is based, in part, on 
the hypothesis that the use of SSRIs may increase the risk of 
suicidality (thoughts and behaviors), this review examines how
suicidality has been measured in randomized controlled trials
(RCTs) of SSRI use in children and adolescents with MDD.
METHODS: The tiered search strategy included RCTs published
between January 1, 1985 and October 31, 2004. Three electronic
bibliographic databases (Medline, PsycINFO, and Dissertation
Abstracts) and the Cochrane Libraries were searched for research
articles meeting the deﬁned inclusion criteria for children and
adolescents. RESULTS: Eight randomized controlled trials met
the inclusion criteria. All eight studies had a general recording
of adverse events, but only four utilized one or more formalized
measure(s) of suicidality. Two of the measures consisted of only
one item related to suicidal ideation, and not all measures used
had been previously validated. CONCLUSIONS: No consistent
methods for deﬁning or measuring suicidality were employed
across studies, even those used to rationalize the FDA warning.
Furthermore, when suicidality was measured, only a part of sui-
cidality was formally measured. Future research should utilize
consistent deﬁnitions and validated measurements of suicidality
so that the risks associated with SSRIs in children and adoles-
cents with MDD will be accurately understood and effectively
compared.
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OBJECTIVES: To compare and contrast the Exhaustive CHAID
classiﬁcation tree to forward stepwise LR in explaining the pre-
scribing of antidepressants in terms of identifying explanatory
variables and interaction effects, accuracy, sensitivity, speciﬁ-
city, and Receiver Operating Characteristic (ROC) analysis.
METHODS: Throughout 1997–2001, National Ambulatory
Medical Care Survey (NAMCS) data was used. The dependent
variable was the prescribing of antidepressants and the explana-
tory variables were 13 variables associated with the patient and
physician characteristics. The data was randomly divided by 7 :
3 for training set and test set. The training set was used to train
the Exhaustive CHAID and forward stepwise LR models and the
test set was used to evaluate the performance of both models.
RESULTS: About 6.7% of the 113,128 ofﬁce visits analyzed had
been prescribed at least 1 antidepressant. While the forward step-
wise LR resulted to all 13 explanatory variables as signiﬁcant,
the Exhaustive CHAID identiﬁed 11 explanatory variables and
3 interactions as signiﬁcantly associated with the prescribing of
antidepressants. The Pearson correlation of the predicted logits
from both models was 0.76492 (p < 0.001). At cut point of 0.5,
the classiﬁcation accuracy, sensitivity, and speciﬁcity of Exhaus-
tive CHAID were 0.95, 0.51, and 0.98 respectively, and were
0.95, 0.36, and 0.99 correspondingly for forward stepwise LR.
The area under the ROC curve of Exhaustive CHAID (0.8610)
slightly and signiﬁcantly outperformed that of forward stepwise
LR (0.8507). CONCLUSIONS: The performance of Exhaustive
CHAID was at least as comparable with forward stepwise LR.
In addition, Exhaustive CHAID has the capacity to automati-
cally detect interaction effects without having to specify a priori
the potential interaction terms. The Exhaustive CHAID produces
a more parsimonious model by using fewer variables to explain
the dependent variable. The resulting classiﬁcation tree also 
provides a visually informative structure on how variables are
selected into the model by their relative contributions.
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OBJECTIVES: Major depressive episodes (MDE) and anxiety
are associated with decreased health-related quality of life
(HRQL). The EQ-5D assesses ﬁve domains, including the single
domain of Anxiety/Depression. Thus, the EQ-5D may be limited
in differentiating among subjects with either or both of MDE
and anxiety disorders. Our objective was to determine the ability
of the EQ-5D to differentiate among persons with MDE or
anxiety alone or in combination, compared with neither.
METHODS: Data were collected in 2003 as part of the Alberta
Mental Health Survey and were obtained through random digit
dialing and computer assisted telephone interviews. MDE and
anxiety were deﬁned by DSM-IV using the Mini International
Neuropsychiatric Interview. HRQL was measured with the 
EQ-5D; responses on the Anxiety/Depression domain were
dichotomized to 1) no problem, or 2) moderate/extreme prob-
lems. Descriptive and multivariate analyses were used to examine
associations between EQ-5D scores and mental health diagnoses.
RESULTS: The average age of the sample (n = 5383) was 40.8
(12.1) years, 61% were female. The prevalence for diagnoses
(and proportion within each group reporting problems on the
Anxiety/Depression domain) were: MDE alone 2.6% (48.6%);
anxiety alone 11.3% (38.7%); MDE and anxiety 5.2% (80.8%);
and neither 80.9% (8.2%), respectively. Compared with subjects
with neither condition, after adjustment for socio-demographic
variables, mean EQ-Index and EQ-VAS scores were signiﬁcantly
lower for subjects with MDE and anxiety (0.70, 64.2), followed
by those with MDE alone (0.83, 70.8) and anxiety alone (0.84,
76.7). CONCLUSIONS: Respondents with MDE or anxiety
alone reported similar burden on the EQ-5D, overall and on the
Anxiety/Depression domain. Comorbid MDE and anxiety is
reﬂected in substantially lower EQ-5D scores. The EQ-5D per-
forms reasonably well as a measure of general mental health, but
more in-depth and speciﬁc measures would be required to iden-
tify and differentiate the impact of isolated mental health con-
ditions on HRQL.
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OBJECTIVES: Depression-free days (DFD) and quality-adjusted
days (QAD) are used to assess the overall effectiveness of anti-
depressants for patients with major depressive disorder (MDD).
Both metrics estimate utility based on fractions from scores on
the Hamilton Rating Scale for Depression (HAM-D). The objec-
tive of this study was to develop a new patient-preference
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weighted metric. METHODS: Data were pooled from two 
identical ten-week, multicenter, randomized, double-blind,
placebo-controlled studies of ﬂexible-dose venlafaxine XR
(37.5–300mg/day; mean daily doses in the individual studies
were 132mg and 130mg) and sertraline (50–200mg/day; mean
daily doses in the individual studies were 89mg and 88mg) in
the treatment of DSM-IV MDD (1352 ITT patients). Three
health states were deﬁned using HAM-D17 scores: remission =
HAM-D £ 7; response = HAM-D between eight and 15; no
response = HAM-D > 15. The extended individual model of
Quality-Adjusted Time Without Symptoms and Toxicity (Q-
TWiST) method was applied to develop quality-adjusted remis-
sion days (QUARE), which evaluates treatment trade-offs by
incorporating the duration and patient preference (ie, utility)
associated with each health state. Effectiveness was measured by
the treatment difference on average QUARE days using an
ANOVA model with center as a covariate. Threshold utility
analysis was applied to address the utility uncertainty as a sen-
sitivity analysis. RESULTS: Over the ten-week acute treatment
period, venlafaxine XR was associated with signiﬁcantly more
QUARE days than placebo at all possible utility scenarios (P <
0.05). Sertraline was also associated with signiﬁcantly more
QUARE days than placebo at majority of possible utility sce-
narios. CONCLUSIONS: QUARE is a utility-based measure that
could be used as QALY (Quality Adjusted Life Years) directly in
cost-effectiveness studies. Different deﬁnitions of health states
can be applied to derive QUARE in MDD. Venlafaxine XR and
sertraline were associated with signiﬁcantly more QUARE days
than placebo in ten-week acute treatment of MDD.
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Depression is ranked as having the fourth greatest disease burden
worldwide measured by Disability Adjusted Life Years (DALYs).
Despite the impact of depression on overall morbidity, a signiﬁ-
cant proportion of patients go undiagnosed because the presence
of somatic and painful physical symptoms masks depression.
OBJECTIVES: The aim of this literature review is 1) to assess
existing Patient Reported Outcome (PRO) instruments validated
for use in depression; and 2) to identify to what extent they cover
the whole range of symptoms, especially those somatic and
painful physical symptoms that might hinder recognition of
depression. METHODS: A systematic literature review of pub-
lished studies was conducted using MEDLINE (1951–2004),
EMBASE (1974–2004), and the Mapi Research Trust databases.
Only studies with named, referenced PRO instruments used in
depressed patients were reviewed. The search was restricted to
idiopathic depression. RESULTS: Fifty-nine PRO instruments
were identiﬁed and of those with sufﬁcient data on psychomet-
ric properties, 22 retained for review. Of these, six covered pri-
marily emotional symptoms, three covered somatic symptoms
and 13 both. Excluding the six PRO instruments focused on
emotional symptoms, 16 instruments (eight Quality of Life, two
Activities-of-Daily-Living, four Utility, one Satisfaction and one
Work Productivity) were included in the review. Despite the
variety of PRO instruments covering a wide range of domains,
only a small number presented comprehensive psychometric val-
idation. Indeed, only ﬁve instruments were studied for their
responsiveness to clinical change. CONCLUSION: No single
instrument provides comprehensive coverage of all symptoms of
depression (including emotional, somatic and painful physical
symptoms) and a well documented psychometric validation
status. This literature review suggests the need for additional
work on the responsiveness of instruments in assessing physical
symptoms of depression, as well as further development of
patient satisfaction and work productivity questionnaires.
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AND AFTER TREATMENT WITH ATYPICAL ANTIPSYCHOTICS
Rajagopalan K1, Lage MJ2
1AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA;
2HealthMetrics Outcomes Research, Groton, CT, USA
OBJECTIVE: Examine the mean difference in hospitalization
and emergency room (ER) visit rates pre and post-initiation on
olanzapine, quetiapine or risperidone. METHODS: Retrospec-
tive analysis of a commercial claims database capturing inpa-
tient, outpatient and prescription drug services. Individuals
having a mental illness diagnosis, and initiated with olanzapine
(N = 8730), quetiapine (N = 5709) or risperidone (N = 9339)
between July 1, 1998 and July 2, 2002 were identiﬁed. Mean
differences in the hospitalization or ER visit rates between the
pre- and post- six month periods across the three-treatments
were examined using ANCOVA, controlling for age, gender,
region, and type of mental illness diagnosis. RESULTS: Individ-
uals initiated with olanzapine or risperidone were found to have
a signiﬁcantly higher difference in the hospitalization (2.19%, p
< 0.0001; 1.72%, p < 0.0001) or ER visit rates (3.80, p < 0.0001;
4.60%, p < 0.0001) post initiation of medication compared to
the six months prior to initiation of medication. In contrast, indi-
viduals who were initiated with quetiapine had a signiﬁcantly
lower difference in the hospitalization (-4.37%, p < 0.0001) or
ER visit rates (-2.89%, p < 0.0001) post-initiation of quetiap-
ine compared to the six months prior-initiation of quetiapine.
CONCLUSION: Quetiapine, unlike olanzapine or risperidone,
may be associated with fewer hospitalizations and ER visits 
after medication initiation. These results may be suggestive of a
more favorable side effect proﬁle and/or better compliance with
Quetiapine, and needs further investigation.
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OBJECTIVE: The severe and persistently mentally (SPMI) have
greater rates of metabolic disorders than the general population
(GP). Wellness programs have demonstrated a reduction in
health care costs for the GP. A program designed to reduce the
rate of metabolic disorders and their risk factors may prove to
signifcantly reduce annual health care cost in the SPMI. The
study goal was to evaluate the effect on metabolic syndrome 
risks of a psychoeducation program designed for SPMI.
METHOD: Overweight patients were randomly selected for 
participation in the study. A psychoeducation program 
which included modules on nutrition and active exercise was
developed and tested. The study had a acute(1hr. 3 X week)
phase for three-months and a maintenance phase (1hr. 1 X
month) for three-months. Vitals and lab tests were taken every
